Michael T. Flavin, Ph.D., Chief Executive Officer and Chairman, founded Advanced Life
Sciences, Inc. in 1999. Prior to this date, he was the founder, Chief Executive Officer and Chairman of
MediChem Life Sciences, Inc., a drug discovery technology and services company. Dr. Flavin took
MediChem from start-up in 1987 through many stages of development including the completion of
MediChem’s private placement, the acquisition and integration of ThermoGen and Emerald
Biostructures as MediChem subsidiaries and MediChem’s initial public offering in October of 2000.
MediChem was acquired in 2002 by deCODE genetics. Dr. Flavin received a B.S. in Chemistry from
the University of Notre Dame, a Ph.D. in Medicinal Chemistry from the University of Illinois at
Chicago and he completed a postdoctoral fellowship at Harvard University. Dr. Flavin is an Adjunct
Professor for the Department of Medicinal Chemistry & Pharmacognosy at the University of Illinois at
John L. Flavin, M.B.A., President and Director, joined us in June 2002 as Executive Vice President and
Chief Financial Officer. He was elected to our board of directors in 2003 and promoted to President in
2004. Mr. Flavin was formerly the Chief Operating Officer and a director of MediChem Life
Sciences, Inc. At MediChem, Mr. Flavin was responsible for developing and managing the business and
scientific operations and was the Chief Executive Officer of its protein engineering and structural
proteomics subsidiaries, Emerald BioStructures, ThermoGen and AXAS. Mr. Flavin holds a B.S. in
Business Administration from Marquette University and an M.B.A. from Lewis University.
Terry W. Osborn, Ph.D., Director, joined our board of directors in July 2001. Dr. Osborn is a
pharmaceutical executive with significant experience in establishing strategic direction to develop sales
and enhance profitability in both startup and turnaround environments. He is the President and CEO
of Gene Express, Inc., a genomics company in Toledo, Ohio. Dr. Osborn was previously the Chief
Executive Officer of Pharmaceutical Development Center, a contract formulation, development and
cGMP manufacturer of biopharmaceutical and pharmaceutical drugs. He was also the founder,
President and Chief Executive Officer of Health Advance Institute, a National Clinical Research
Organization providing clinical research services to pharmaceutical and biotechnology companies.
Dr. Osborn received his Ph.D. in Biochemistry from the University of California at Riverside and his
M.B.A. from Pepperdine University.
Israel Rubinstein, M.D., Director, joined our board of directors in May 2001. Dr. Rubinstein is
Professor of Medicine and Biopharmaceutical Sciences in the Colleges of Medicine and Pharmacy at
the University of Illinois at Chicago. Dr. Rubinstein is a leading physician and research scientist in
respiratory medicine and oncology. He has served on the Editorial Boards of several medical journals
and is grant reviewer for the NIH. Dr. Rubinstein received an M.D. degree from Hebrew University-
Hadassah School of Medicine and completed fellowships in Respirology at the University of Toronto
and in Cardiovascular Research at the University of California San Francisco.
Rosalie Sagraves, Pharm.D., Director, joined our board of directors in May 2001. Dr. Sagraves is
Dean and Professor at the University of Illinois at Chicago, College of Pharmacy. Her practice area is
pediatric critical care with educational/research interests in pediatric pharmacotherapeutics and
maternal-child health. She has authored more than 60 journal articles and book chapters. She is a
speaker on pediatric pharmacotherapy and women’s health. Some of her accomplishments include
having served the American Association of Colleges of Pharmacy as Council of Deans chair and
member of AACP board of directors, American Pharmaceutical Association, Academy of
Pharmaceutical Research and Science as president, member of the APhA Board of Trustees and the
editorial board of Pharmacy Today. She is a fellow of APhA and of the American College of Clinical
Pharmacy. She serves on the National Institutes of Health Office of Research on Women’s Health
Advisory Board. She has received awards for outstanding teaching and leadership. She graduated from
the Ohio State University and the Philadelphia College of Pharmacy and Science.
Thomas V. Thornton, Director, joined our board of directors in June 2001. Mr. Thornton is a
successful early-stage venture capital investor and recognized leader in the development of public/
private technology development initiatives. From July 2001 to March 2002, Mr. Thornton was the
Senior Vice President—Midwest Region for Convergent Technology Group, a mergers and acquisitions
advisory services firm. He is also the former Managing Partner for divine interVentures, Inc., a service
and software company, and led seed- and early-stage venture investing teams that managed over
$120 million and contributed to divine interVenture’s initial public offering. Presently, Mr. Thornton is
the president of the Illinois Technology Development Alliance, a public/private partnership established
to strengthen Illinois’ economy through science and technology. Mr. Thornton received a B.A. degree
from the University of Wisconsin-Madison.